NTRA

SEC source: 0001646382-26-000002 · form4-03162026_090301.xml · nonDerivative · entry 1

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,385,772

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0002010135-26-000007 · form4-03112026_090301.xml · nonDerivative · entry 2

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 189,199

F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on March 9, 2026.

SEC source: 0002010019-26-000008 · form4-03112026_060302.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,882

F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on March 9, 2026.

SEC source: 0001711968-26-000008 · form4-03112026_090301.xml · nonDerivative · entry 2

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,607

F3 · shares: The sale of shares was partially effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on March 9, 2026.

SEC source: 0001697362-26-000006 · form4-03112026_090303.xml · nonDerivative · entry 2

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,354

F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on March 9, 2026.

SEC source: 0001857843-26-000009 · form4-03112026_090305.xml · nonDerivative · entry 2

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 233,285

F3 · shares: The sale of shares was partially effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on March 9, 2026.

SEC source: 0001646649-26-000009 · form4-03112026_090303.xml · nonDerivative · entry 2

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 262,325

F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on March 9, 2026.

SEC source: 0002010135-26-000007 · form4-03112026_090301.xml · nonDerivative · entry 1

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 189,906

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs were fully-vested at the time of issuance.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0002010019-26-000008 · form4-03112026_060302.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,797

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs were fully-vested at the time of issuance.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001711968-26-000008 · form4-03112026_090301.xml · nonDerivative · entry 1

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 162,230

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs were fully-vested at the time of issuance.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001697362-26-000006 · form4-03112026_090303.xml · nonDerivative · entry 1

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,139

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs were fully-vested at the time of issuance.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001857843-26-000009 · form4-03112026_090305.xml · nonDerivative · entry 1

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 235,030

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs were fully-vested at the time of issuance.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001646649-26-000009 · form4-03112026_090303.xml · nonDerivative · entry 1

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 262,452

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs were fully-vested at the time of issuance.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001857843-26-000008 · form4-03102026_090301.xml · derivative · entry 7

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,598 shares

Expires 2029-03-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option shares are fully exercisable.

SEC source: 0001857843-26-000008 · form4-03102026_090301.xml · nonDerivative · entry 6

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 233,285

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.45 to $198.32 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001857843-26-000008 · form4-03102026_090301.xml · nonDerivative · entry 5

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 235,283

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.42 to $197.38 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001857843-26-000008 · form4-03102026_090301.xml · nonDerivative · entry 4

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 236,783

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.32 to $196.26 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001857843-26-000008 · form4-03102026_090301.xml · nonDerivative · entry 3

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 238,383

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.27 to $195.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001857843-26-000008 · form4-03102026_090301.xml · nonDerivative · entry 2

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 241,283

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.27 to $194.02 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001857843-26-000008 · form4-03102026_090301.xml · nonDerivative · entry 1

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 241,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0002010019-26-000007 · form4-03032026_090301.xml · derivative · entry 6

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,125 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option shares are fully exercisable.

SEC source: 0002010019-26-000007 · form4-03032026_090301.xml · nonDerivative · entry 5

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,023

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.72 to $201.16 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002010019-26-000007 · form4-03032026_090301.xml · nonDerivative · entry 4

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,498

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.6750 to $200.5100 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002010019-26-000007 · form4-03032026_090301.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 152,092

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.42 to $199.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002010019-26-000007 · form4-03032026_090301.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 153,023

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001711968-26-000007 · form4-03032026_090303.xml · nonDerivative · entry 4

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,607

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024.

F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.80 to $201.27 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001711968-26-000007 · form4-03032026_090303.xml · nonDerivative · entry 3

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,972

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.7150 to $200.6600 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001711968-26-000007 · form4-03032026_090303.xml · nonDerivative · entry 2

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 159,435

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.6500 to $199.5650 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646649-26-000008 · form4-03032026_090305.xml · nonDerivative · entry 5

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 262,194

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

SEC source: 0001646649-26-000008 · form4-03032026_090305.xml · nonDerivative · entry 4

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 262,294

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

SEC source: 0001646649-26-000008 · form4-03032026_090305.xml · nonDerivative · entry 3

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 262,394

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.00 to $200.7950 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646649-26-000008 · form4-03032026_090305.xml · nonDerivative · entry 2

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 264,794

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.24 to $198.85 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002010135-26-000006 · form4-03032026_080303.xml · nonDerivative · entry 1

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 188,132

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs vest over four years. 25% of the RSUs vest on March 1, 2027 and the remaining RSUs vest in 12 equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0002010019-26-000007 · form4-03032026_090301.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 147,898

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs vest over four years. 25% of the RSUs vest on March 1, 2027 and the remaining RSUs vest in 12 equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001711968-26-000007 · form4-03032026_090303.xml · nonDerivative · entry 1

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 160,557

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs vest over four years. 25% of the RSUs vest on March 1, 2027 and the remaining RSUs vest in 12 equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001697362-26-000005 · form4-03032026_080301.xml · nonDerivative · entry 1

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,171

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs vest over four years. 25% of the RSUs vest on March 1, 2027 and the remaining RSUs vest in 12 equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001646382-26-000001 · form4-03032026_080307.xml · nonDerivative · entry 1

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,310,772

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs vest over four years. 25% of the RSUs vest on March 1, 2027 and the remaining RSUs vest in 12 equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001646649-26-000008 · form4-03032026_090305.xml · nonDerivative · entry 1

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 265,264

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs vest over four years. 25% of the RSUs vest on March 1, 2027 and the remaining RSUs vest in 12 equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001857843-26-000006 · form4-03032026_080305.xml · nonDerivative · entry 1

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 236,085

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs vest over four years. 25% of the RSUs vest on March 1, 2027 and the remaining RSUs vest in 12 equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0002010135-26-000005 · form4-02042026_090205.xml · nonDerivative · entry 2

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,081

F2 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 30, 2026.

SEC source: 0002010135-26-000005 · form4-02042026_090205.xml · nonDerivative · entry 1

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 180,496

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.

SEC source: 0002010019-26-000006 · form4-02042026_090205.xml · nonDerivative · entry 7

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 137,847

F6 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.

SEC source: 0001711968-26-000006 · form4-02042026_090203.xml · nonDerivative · entry 7

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,156

F7 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.

SEC source: 0001697362-26-000004 · form4-02042026_090201.xml · nonDerivative · entry 3

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,120

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025, as modified on September 10, 2025.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $226.69 to $227.68 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001697362-26-000004 · form4-02042026_090201.xml · nonDerivative · entry 2

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,091

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025, as modified on September 10, 2025.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.98 to $225.42 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001697362-26-000004 · form4-02042026_090201.xml · nonDerivative · entry 1

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,791

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.

SEC source: 0001646649-26-000007 · form4-02042026_090203.xml · nonDerivative · entry 1

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 263,161

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.

SEC source: 0001857843-26-000005 · form4-02042026_090201.xml · nonDerivative · entry 1

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 223,813

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.

SEC source: 0002010019-26-000006 · form4-02042026_090205.xml · nonDerivative · entry 6

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,486

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

SEC source: 0002010019-26-000006 · form4-02042026_090205.xml · nonDerivative · entry 5

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,502

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $232.94 to $233.82 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.